Internal enhancement of DNA damage by a novel bispecific antibody‐drug conjugate‐like therapeutics via blockage of mTOR and PD‐L1 signal pathways in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a refractory malignant tumor with poor prognosis, limited chemotherapeutic efficacy, and only about 5% of 5‐year survival rate. We generated a dual‐targeting ligand‐based lidamycin (DTLL) to investigate its efficacy against pancreatic cancer after preparing...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Rui, Song, Wenping, Ye, Cheng, Liu, Xiujun, Li, Liang, Li, Yi, Yao, Hongjuan, Zhou, Xiaofei, Shao, Rongguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382721/
https://www.ncbi.nlm.nih.gov/pubmed/30681288
http://dx.doi.org/10.1002/cam4.1974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382721/
https://www.ncbi.nlm.nih.gov/pubmed/30681288
http://dx.doi.org/10.1002/cam4.1974

Ejemplares similares